摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

1-amino-3-o-tolylpiperidin-2-one | 1123196-15-5

中文名称
——
中文别名
——
英文名称
1-amino-3-o-tolylpiperidin-2-one
英文别名
1-Amino-3-(2-methylphenyl)piperidin-2-one
1-amino-3-o-tolylpiperidin-2-one化学式
CAS
1123196-15-5
化学式
C12H16N2O
mdl
——
分子量
204.272
InChiKey
RVJMZFYSGBXEOJ-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    1.5
  • 重原子数:
    15
  • 可旋转键数:
    1
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.42
  • 拓扑面积:
    46.3
  • 氢给体数:
    1
  • 氢受体数:
    2

反应信息

点击查看最新优质反应信息

文献信息

  • MULTI-CYCLIC COMPOUNDS
    申请人:KIMURA Teiji
    公开号:US20090062529A1
    公开(公告)日:2009-03-05
    A compound represented by the formula (I): or a pharmacologically acceptable salt thereof, wherein Ar 1 represents an imidazolyl group or the like which may be substituted with a C1-6 alkyl group, Ar 2 represents a phenyl group or the like which may be substituted with a C1-6 alkoxy group, X 1 represents a double bond or the like and Het represents a triazolyl group or the like which may be substituted with a C1-6 alkyl group or the like, is effective as a therapeutic or prophylactic agent for a disease caused by Aβ.
    一种由化学式(I)表示的化合物或其药理学可接受的盐,其中Ar1代表可用C1-6烷基基团取代的咪唑基团或类似基团,Ar2代表可用C1-6烷氧基团取代的苯基团或类似基团,X1代表双键或类似基团,Het代表可用C1-6烷基基团或类似基团取代的三唑基团或类似基团,对由Aβ引起的疾病具有治疗或预防作用。
  • PROCESS FOR PREPARING CERTAIN CINNAMIDE COMPOUNDS
    申请人:Nakamura Taiju
    公开号:US20110172427A1
    公开(公告)日:2011-07-14
    This invention relates to a new synthesis, intermediates and precursors leading to a mixture of the compounds 11 and 12 as shown below. It also relates to the resolution of the stereoisomeric mixture to provide in substantial stereochemical purity compound 12. The synthesis of the invention involves preparation of compound 7 and compound 10 as shown below and their reaction to prepare a mixture of compound 11 and compound 12.
    本发明涉及一种新的合成方法、中间体和前体,可导致化合物11和12的混合物。它还涉及对立体异构混合物的分离,以在实质上立体化学纯度下提供化合物12。该发明的合成涉及制备化合物7和化合物10,如下所示,并将它们反应以制备化合物11和化合物12的混合物。
  • IMIDAZOYL PYRIDINE COMPOUNDS AND SALTS THEREOF
    申请人:KIMURA Teiji
    公开号:US20110065696A1
    公开(公告)日:2011-03-17
    A compound represented by the formula (I): or a pharmacologically acceptable salt thereof, wherein Ar 1 represents an imidazolyl group or the like which may be substituted with a C1-6 alkyl group, Ar 2 represents a phenyl group or the like which may be substituted with a C1-6 alkoxy group, X 1 represents a double bond or the like and Het represents a triazolyl group or the like which may be substituted with a C1-6 alkyl group or the like, is effective as a therapeutic or prophylactic agent for a disease caused by Aβ.
    化合物的化学式为(I)或其药理学上可接受的盐,其中Ar1代表咪唑基团或类似基团,该基团可能被C1-6烷基取代,Ar2代表苯基或类似基团,该基团可能被C1-6烷氧基取代,X1代表双键或类似基团,Het代表三唑基团或类似基团,该基团可能被C1-6烷基或类似基团取代,可用作治疗或预防由Aβ引起的疾病的药物。
  • Polycyclic compound
    申请人:Eisai R&D Management Co., Ltd.
    公开号:EP2559693A1
    公开(公告)日:2013-02-20
    Disclosed is a compound represented by the formula (I-1): or a pharmacologically acceptable salt thereof, which is effective as a therapeutic or prophylactic agent for a disease induced by Aβ, wherein X1 represents -CH=CH- and Het represents a group which may be substituted with 1 to 3 substituents selected from substituents group A1 and is represented by one of the following formulas:
    本发明公开了一种由式(I-1)表示的化合物: 或其药理上可接受的盐,可有效治疗或预防由 Aβ 诱导的疾病,其中 X1 代表-CH=CH-,Het 代表可被 1 至 3 个选自取代基 A1 的取代基取代的基团,并由下式之一表示:
  • US7935815B2
    申请人:——
    公开号:US7935815B2
    公开(公告)日:2011-05-03
查看更多